ACRS VS NVO Stock Comparison
Performance
ACRS10/100
10/100
ACRS returned -96.22% in the last 12 months. Based on SPY's performance of -11.17%, its performance is below average giving it a score of 10 of 100.
NVO100/100
100/100
NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
ACRS92/100
92/100
6 analysts offer 12-month price targets for ACRS. Together, they have an average target of 25, the most optimistic target put ACRS at 25 within 12-months and the most pessimistic has ACRS at 25.
NVO50/100
50/100
1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.
Sentiment
ACRS69/100
69/100
ACRS had a bullish sentiment score of 68.61% across Twitter and StockTwits over the last 12 months. It had an average of 32.27 posts, 12.68 comments, and 65.86 likes per day.
NVO
"Sentiment" not found for NVO
Technicals
ACRS14/100
14/100
ACRS receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
NVO50/100
50/100
NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
ACRS10/100
10/100
ACRS has missed earnings 8 times in the last 20 quarters.
NVO46/100
46/100
NVO has missed earnings 3 times in the last 20 quarters.
Profit
ACRS10/100
10/100
Out of the last 20 quarters, ACRS has had 0 profitable quarters and has increased their profits year over year on 0 of them.
NVO90/100
90/100
Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.
Volatility
ACRS42/100
42/100
ACRS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
NVO53/100
53/100
NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Aclaris Therapeutics, Inc. Summary
Nasdaq / ACRS
Healthcare
Medical - Diagnostics & Research
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Novo-Nordisk A/S Summary
New York Stock Exchange / NVO
Healthcare
Biotechnology
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ACRS to other companies in the same or a similar industry.